Comparing Eyenovia (NASDAQ:EYEN) & Cocrystal Pharma (NASDAQ:COCP)

Eyenovia (NASDAQ:EYEN) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Eyenovia and Cocrystal Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyenovia	0	0	3	0	3.00
Cocrystal Pharma	0	0	1	0	3.00

Eyenovia currently has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Cocrystal Pharma has a consensus target price of $10.00, suggesting a potential upside of 354.55%. Given Eyenovia’s higher probable upside, research analysts plainly believe Eyenovia is more favorable than Cocrystal Pharma.

Insider & Institutional Ownership

25.8% of Eyenovia shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 7.1% of Eyenovia shares are held by company insiders. Comparatively, 25.6% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Eyenovia and Cocrystal Pharma’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyenovia	N/A	N/A	-$27.26 million	($0.75)	-1.92
Cocrystal Pharma	N/A	N/A	-$17.98 million	($1.74)	-1.26

Eyenovia is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eyenovia and Cocrystal Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eyenovia	N/A	-322.68%	-100.51%
Cocrystal Pharma	N/A	-61.61%	-55.60%

Risk & Volatility

Eyenovia has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

About Eyenovia

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.